FH-006 vs physician's choice chemotherapy for ESCC after PD-1/PD-L1 + platinum failure
Official title: A Randomized, Open-label, Multicenter, Phase III Study of FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
Run by Jiangsu HengRui Medicine Co., Ltd. · NCT07790380 · Data updated 2026-11-12
This study tests whether FH-006 helps people with esophageal squamous cell carcinoma live longer than the physician’s choice second-line chemotherapy after prior PD-1/PD-L1 inhibitors with platinum have stopped working.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 480 (estimated) |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. Industry-sponsored |
| Drugs / interventions | Chemotherapy, immunotherapy |
| Locations | 1 site (Jinan, Shandong) |
| Status | Recruiting |
| Started | October 13, 2026 |
| Main results expected | June 30, 2029 |
| Study ends | June 30, 2029 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07790380 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 with histologically confirmed ESCC, measurable disease, ECOG 0–1, and progression after PD-1/PD-L1 inhibitor plus platinum therapy.
✕Probably not a fit
Patients with uncontrolled brain metastases, recent anti-tumor therapy, or severe organ dysfunction may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this phase 3 trial, adults with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma who progressed after prior PD-1/PD-L1 inhibitor plus platinum therapy are randomized to receive FH-006 or the investigator-selected chemotherapy (paclitaxel, docetaxel, or irinotecan). Primary endpoint is overall survival; secondary endpoints may include response rate and progression-free survival. Eligibility requires good performance status, measurable disease, and adequate organ function, with no recent anti-cancer therapy and no active brain metastases. The trial is led by Jiangsu HengRui Medicine Co., Ltd., with the Shandong Provincial Cancer Hospital as the participating site.
Why it matters
Potential benefit: If FH-006 shows a survival advantage, patients could have a more effective second-line treatment option after PD-1/PD-L1 inhibitor failure.
How similar studies have gone: Prior studies in similar settings have explored alternative second-line regimens; the success of FH-006 in this exact context is not yet established and remains to be proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 to 75 years old (including boundary values) 2. Volunteer to participate in this clinical study and sign informed consent; 3. ECOG score 0-1; 4. Expected survival ≥3 months; 5. Patients diagnosed with esophageal squamous cell carcinoma by histological or cytological examination; 6. Previously, only PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy were received; 7. There is at least one measurable lesion that meets the RECIST 1.1 criteria; 8. Adequate bone marrow and organ function. Exclusion Criteria: 1. Received anti-tumor therapies such as chemotherapy, radiotherapy, biological therapy, targeted therapy, or immunotherapy within 4 weeks before the first dose of the study 2. Toxicities caused by previous anticancer therapy were not recovered to CTCAE 6.0 Grade≤1; 3. Individuals with Leptomeningeal metastasis or Active brain metastases; 4. Individuals with a history of GI perforation or fistula, unstable GI bleeding; 5. Individuals with a history of severe cardiovascular and cerebrovascular diseases; 6. The researcher determined that there are other situations that are not suitable for participation.
Where it's running
-
Shandong Provincial Cancer Hospital
Jinan, Shandong, China Recruiting
Study contacts
- Study coordinator: Shilong Yu
- Email: lin.ma.lm60@hengrui.com
- Phone: +86-021-23511999
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HRS-7172 with other cancer drugs in advanced pancreatic cancer
This study tests if HRS-7172 added to standard cancer therapies can help people with advanced pancreatic cancer that has RAS mutations or amplifications.
-
HRS-9190 vs Rocuronium for Muscle Relaxation During Anesthesia
This Phase 3 trial tests whether HRS-9190 can provide effective muscle relaxation for intubation and surgery as compared with rocuronium in adults undergoing elective general anesthesia.
-
HRS-7525 tablets in advanced prostate cancer
This study tests whether HRS-7525 tablets can be safely given to men with advanced prostate cancer and helps find a tolerable dose for future tests.
-
HRS-3005 in B-cell Malignancies
This early-phase study tests HRS-3005 in adults with relapsed or refractory B-cell cancers to see if it is safe and tolerable and to find a suitable dose for future studies.
-
Trastuzumab Rezetecan versus Trastuzumab Deruxtecan for unresectable HER2‑low, HR‑positive breast cancer
This Phase 2 trial tests different doses of Trastuzumab Rezetecan compared with Trastuzumab Deruxtecan in women with HR-positive, HER2-low unresectable locally recurrent or metastatic breast cancer to see which dose is safer and more effective.
-
Comparing bioavailability and safety of different SHR-3167 injection formulations
This trial will test how different formulations of the SHR-3167 injection are absorbed and whether they are safe in healthy adults aged 18–55.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.